Close Menu

Takara Bio

An international team of researchers put nine immune cell sequencing methods head to head, including RNA-based and DNA-based ones, using the same T-cell sample.

The firm's SmartChip platform consists of a high-throughput liquid dispenser and a PCR instrument and can provide more than 5,000 reactions in one run.

The new method uses Takara Bio's SmartChip PCR instrument, chips, and reagents to run 5,184 reactions per chip in less than 30 minutes.

Both studies emerged from the ongoing Human Cell Atlas project and could help scientists decide on the best approaches to use in various contexts.

The partners will use Namocell's single-cell dispensing tool and Takara's Smart-seq technology to isolate and characterize HepaTx's hepatocyte-like cells. 

According to Takara, the workflow allows researchers to use 25 percent of the primers and enzymes required by conventional single-cell methods.

The preliminary revenue results come ahead of the company's planned merger with Takara Bio USA Holdings.

The deal is expected to help Takara Bio Group expand its presence in next-generation sequencing library preparation and other markets.

The deal is expected to broaden Takara's portfolio of products for next-generation sequencing library preparation and genetic analysis.

The firm recently enacted a 1-for-5 reverse stock split to help its shares meet the minimum bid price requirement for listing on the market.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.